Dopamine News and Research

Latest Dopamine News and Research

Ceregene initiates enrollment and dosing in CERE-120 Phase 2b trial for Parkinson's disease

Ceregene, a biopharmaceutical company, announced today that it is progressing with enrollment and dosing in its CERE-120 Phase 2b multi-center, sham-surgery, double-blinded controlled trial in Parkinson's disease.

3 Feb 2011

Ritalin may help improve brain function in children with iron deficiency

Ritalin may help improve brain function in adolescent rats that were iron deficient during infancy, according to a team of Penn State neuroscientists. This may have implications for iron-deficient human infants as well.

3 Feb 2011

Defective nucleoli linked to Parkinson's disease

"Nucleolus", or small nucleus, is the term coined by early biologists for the tiny structure within the nucleus which they saw under the microscope. In this structure within the nucleus, RNA molecules and proteins are assembled to form ribosomes, the true protein factories of cells.

2 Feb 2011

Gut bacteria may influence mammalian brain development and adult behavior

A team of scientists from across the globe have found that gut bacteria may influence mammalian brain development and adult behavior. The study is published in the scientific journal PNAS, and is the result of an ongoing collaboration between scientists at Karolinska Institutet in Sweden and the Genome Institute of Singapore.

1 Feb 2011

New nicotine addiction mechanism revealed

A new discovery has shown why some people cannot give up tobacco and may lead to new anti-smoking treatments. The researchers have found a brain pathway which when defective leads to an uncontrollable desire to smoke. This is a “sub-unit” of a receptor protein sensitive to nicotine.

31 Jan 2011

First three-dimensional projectome map of intact brain

It would be hard to understand how a city is organized without knowledge of the course of all of its streets. Scientists confront the same problem when trying to understand the functioning of the brain. In the case of vertebrates, we only have fragmentary knowledge of which nerve cells send their connections, so-called axons, into certain regions of the brain.

27 Jan 2011

FDA approves Clinical Data's Viibryd for major depressive disorder

Clinical Data, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved vilazodone HCl tablets, to be marketed under the brand name Viibryd™, for the treatment of adults with major depressive disorder (MDD).

24 Jan 2011

Damaged alpha-synuclein proteins can spread in a 'prion-like' manner: Study

The study, published in the Journal of Clinical Investigation, reveals that damaged alpha-synuclein proteins can spread in a 'prion-like' manner, an infection model previously described for diseases such as BSE.

20 Jan 2011

Study demonstrates role of alpha-synuclein cell-to-cell transfer in Parkinson's disease pathogenesis

The misfolding of abnormal proteins in brain cells is a key element in Parkinson's disease development. A recent study suggests that the sick proteins slowly move between cells, eventually triggering the destruction of the new host cell. The discovery could potentially lead to new therapeutic strategies for neurodegenerative diseases aimed at blocking the spread of protein misfolding throughout the brain.

19 Jan 2011

Deep brain stimulation stabilizes motor symptoms in Parkinson's disease over time

Parkinson's disease symptoms begin subtly and worsen as damage to certain brain cells continues. But an electrical stimulation device implanted deep in the brain and programmed remotely, along with medications, may provide some control of "motor symptoms" common to the disease, such as shaking, stiffness, and loss of muscle control.

19 Jan 2011

The neuroscience of musical chills

Scientists have found that the pleasurable experience of listening to music releases dopamine, a neurotransmitter in the brain important for more tangible pleasures associated with rewards such as food, drugs and sex. The new study from The Montreal Neurological Institute and Hospital - The Neuro at McGill University also reveals that even the anticipation of pleasurable music induces dopamine release [as is the case with food, drug, and sex cues].

13 Jan 2011

Unique vaccine produces long-lasting anti-cocaine immunity in mice

Researchers from The Scripps Research Institute, Weill Cornell Medical College, and Cornell University have produced a long-lasting anti-cocaine immunity in mice by giving them a unique vaccine that combines bits of the common cold virus with a particle that mimics cocaine.

5 Jan 2011

Researchers develop unique vaccine that produces long-lasting anti-cocaine immunity in mice

5 Jan 2011

Whites with mutations more likely to be susceptible to cocaine abuse

Nearly one in five whites could carry a genetic variant that substantially increases their odds of being susceptible to severe cocaine abuse, according to new research.

21 Dec 2010

Ipsen discontinues development of chimeric compound BIM 23A760 for acromegaly

Ipsen announced today that the preliminary data from the ongoing phase IIb study in patients with acromegaly for its chimeric compound BIM 23A760 does not meet the expected inhibition of growth hormone (GH) and IGF-1 levels after repeat dosing. Preliminary phase IIb data showed a strong dopaminergic activity but only weak evidence of somatostatinergic activity.

15 Dec 2010

Research sheds new light on dopamine's role in brain's reward system

Researchers have shed new light on dopamine's role in the brain's reward system, which could provide insight into impulse control problems associated with addiction and a number of psychiatric disorders.

9 Dec 2010

Rexahn presents data from Serdaxin Phase IIa study at 49th ACNP Annual Meeting

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the presentation of data from its proof of concept study with lead CNS compound Serdaxin® at the 49th American College of Neuropsychopharmacologists (ACNP) Annual Meeting, held in Miami Beach, FL, December 5-9, 2010 at the Fountainbleau Resort.

9 Dec 2010

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Sunovion Pharmaceuticals Inc. today announced the results of the PEARL 3 study, the third phase 3 worldwide clinical trial of Latuda® (lurasidone HCl) tablets, a once-daily atypical antipsychotic agent recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with schizophrenia. In this six-week, placebo-controlled trial, both fixed doses of LATUDA 80 and 160 mg once-daily, demonstrated statistically significant improvement in symptoms of schizophrenia versus placebo across both primary and secondary efficacy measures.

9 Dec 2010

Euthymics announces EB-1010 Phase II data for major depressive disorder at ACNP meeting

9 Dec 2010

Euthymics's EB-1010 effective in treatment of major depressive disorder: Study

Euthymics Bioscience, Inc. today will present Phase II clinical data demonstrating that its lead product candidate EB-1010, a next-generation antidepressant, is effective for treating major depressive disorder (MDD) based on multiple standard measures of outcome for depression. EB-1010 also improved measures of anhedonia, a hallmark symptom of MDD, which is characterized by the inability to experience pleasure.

9 Dec 2010

Dopamine News and Research

Latest Dopamine News and Research

Ceregene initiates enrollment and dosing in CERE-120 Phase 2b trial for Parkinson's disease

Ritalin may help improve brain function in children with iron deficiency

Defective nucleoli linked to Parkinson's disease

Gut bacteria may influence mammalian brain development and adult behavior

New nicotine addiction mechanism revealed

First three-dimensional projectome map of intact brain

FDA approves Clinical Data's Viibryd for major depressive disorder

Damaged alpha-synuclein proteins can spread in a 'prion-like' manner: Study

Study demonstrates role of alpha-synuclein cell-to-cell transfer in Parkinson's disease pathogenesis

Deep brain stimulation stabilizes motor symptoms in Parkinson's disease over time

The neuroscience of musical chills

Unique vaccine produces long-lasting anti-cocaine immunity in mice

Researchers develop unique vaccine that produces long-lasting anti-cocaine immunity in mice

Whites with mutations more likely to be susceptible to cocaine abuse

Ipsen discontinues development of chimeric compound BIM 23A760 for acromegaly

Research sheds new light on dopamine's role in brain's reward system

Rexahn presents data from Serdaxin Phase IIa study at 49th ACNP Annual Meeting

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Euthymics announces EB-1010 Phase II data for major depressive disorder at ACNP meeting

Euthymics's EB-1010 effective in treatment of major depressive disorder: Study

Quality, Patient Safety and Innovation Manager at Elsevier

How Bruker worked with the University of Manchester on mapping the dynamics of complex protein

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Dopamine News and Research

Latest Dopamine News and Research

Quality, Patient Safety and Innovation Manager at Elsevier

How Bruker worked with the University of Manchester on mapping the dynamics of complex protein

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Newsletters you may be interested in